FTC orders divestiture based on harm to suppliers

Kaela Cote-Stemmermann

02 August 2018

The Federal Trade Commission has cleared global healthcare company Grifols to buy Biotest on the condition that it sells certain assets, after raising concerns about harm to the market for the supply of blood as well as the sale of hepatitis B immune globulin.

Subscribe to Global Competition Review

Subscribe and start reading now

Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.

Subscribe now

Already have access? Login below

Kaela Cote-Stemmermann

View full biography

Author

[email protected]

Tipline

Sigh of the Times: The Tipline for 19 January 2021
Antitrust defendants let out a collective sigh of relief on Monday as President-elect Joe Biden announced his selection of Rohit Chopra to lead the Consumer Financial Protection Bureau. It remains unclear who will fill Chopra’s seat at the Federal Trade Commission, but Biden may be hard-pressed to find a competition enforcer as aggressive as the outgoing Democrat. Also in Tipline, the ASCAP/BMI consent decrees survive another review and the FTC quarrels over healthcare advocacy. …
Makan waves: The Tipline for 15 January 2021
Restitution from the wicked: The Tipline for 14 January 2021